Literature DB >> 9736741

HIV type I envelope determinants for use of the CCR2b, CCR3, STRL33, and APJ coreceptors.

T L Hoffman1, E B Stephens, O Narayan, R W Doms.   

Abstract

The envelope (Env) proteins of primate lentiviruses interact sequentially with CD4 and a coreceptor to infect cells. Changes in coreceptor use strongly influence viral tropism and pathogenesis. We followed the evolution of coreceptor use in pig-tailed macaques that developed severe CD4 T-cell loss during the derivation of a pathogenic simian HIV (SHIV) that contained the tat, rev, vpu, and env genes of the HXBc2 strain of HIV-1 in a genetic background of SIVmac239. The Env from the parental virus as well as one derived from the first macaque to develop AIDS exclusively used CXCR4 as a coreceptor, indicating that CXCR4 can function as a coreceptor in macaques even though it is rarely used by simian immunodeficiency viruses. One Env (Pnb5), obtained from a macrophage-tropic virus isolated from the cerebral spinal fluid, did not use CCR5 or CXCR4. Instead, it used CCR2b and to a lesser extent CCR3, STRL33, and APJ to infect cells. Chimeras between Pnb5 and the parental X4 Env indicated that the V3 loop is the major determinant of CXCR4 use, with other regions of Env influencing the efficiency with which this coreceptor was used. In contrast, the Pnb5 V1/2 and V3 regions in combination were both necessary and sufficient to confer full use of CCR2b, CCR3, STRL33, and APJ to the parental X4 Env protein. These results are consistent with a single, conserved binding site in Env that interacts with multiple coreceptors in conjunction with the V1/2 and V3 loops, and suggest that the V1/2 region plays a more important role in governing the use of CCR2b, CCR3, STRL33, and APJ than for CXCR4.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9736741      PMCID: PMC21647          DOI: 10.1073/pnas.95.19.11360

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  55 in total

1.  Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: analysis by single amino acid substitution.

Authors:  J J De Jong; A De Ronde; W Keulen; M Tersmette; J Goudsmit
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

2.  Infection of cynomolgus monkeys with a chimeric HIV-1/SIVmac virus that expresses the HIV-1 envelope glycoproteins.

Authors:  J Li; C I Lord; W Haseltine; N L Letvin; J Sodroski
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1992

3.  Utilization of chemokine receptors, orphan receptors, and herpesvirus-encoded receptors by diverse human and simian immunodeficiency viruses.

Authors:  J Rucker; A L Edinger; M Sharron; M Samson; B Lee; J F Berson; Y Yi; B Margulies; R G Collman; B J Doranz; M Parmentier; R W Doms
Journal:  J Virol       Date:  1997-12       Impact factor: 5.103

4.  Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule.

Authors:  R A Fouchier; M Groenink; N A Kootstra; M Tersmette; H G Huisman; F Miedema; H Schuitemaker
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

Review 5.  Chemokine receptors and human immunodeficiency virus infection.

Authors:  P D Bieniasz; B R Cullen
Journal:  Front Biosci       Date:  1998-01-01

6.  Identification of human immunodeficiency virus envelope gene sequences influencing viral entry into CD4-positive HeLa cells, T-leukemia cells, and macrophages.

Authors:  B Chesebro; J Nishio; S Perryman; A Cann; W O'Brien; I S Chen; K Wehrly
Journal:  J Virol       Date:  1991-11       Impact factor: 5.103

7.  Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1.

Authors:  S S Hwang; T J Boyle; H K Lyerly; B R Cullen
Journal:  Science       Date:  1991-07-05       Impact factor: 47.728

8.  Small amino acid changes in the V3 hypervariable region of gp120 can affect the T-cell-line and macrophage tropism of human immunodeficiency virus type 1.

Authors:  T Shioda; J A Levy; C Cheng-Mayer
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-15       Impact factor: 11.205

9.  Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population.

Authors:  H Schuitemaker; M Koot; N A Kootstra; M W Dercksen; R E de Goede; R P van Steenwijk; J M Lange; J K Schattenkerk; F Miedema; M Tersmette
Journal:  J Virol       Date:  1992-03       Impact factor: 5.103

10.  Human immunodeficiency virus type 1 clones chimeric for the envelope V3 domain differ in syncytium formation and replication capacity.

Authors:  J J de Jong; J Goudsmit; W Keulen; B Klaver; W Krone; M Tersmette; A de Ronde
Journal:  J Virol       Date:  1992-02       Impact factor: 5.103

View more
  38 in total

1.  Functional dissection of CCR5 coreceptor function through the use of CD4-independent simian immunodeficiency virus strains.

Authors:  A L Edinger; C Blanpain; K J Kunstman; S M Wolinsky; M Parmentier; R W Doms
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

2.  Identification and comparison of eleven rhesus macaque chemokine receptors.

Authors:  B J Margulies; D A Hauer; J E Clements
Journal:  AIDS Res Hum Retroviruses       Date:  2001-07-01       Impact factor: 2.205

3.  Stable exposure of the coreceptor-binding site in a CD4-independent HIV-1 envelope protein.

Authors:  T L Hoffman; C C LaBranche; W Zhang; G Canziani; J Robinson; I Chaiken; J A Hoxie; R W Doms
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-25       Impact factor: 11.205

4.  Cooperation of the V1/V2 and V3 domains of human immunodeficiency virus type 1 gp120 for interaction with the CXCR4 receptor.

Authors:  B Labrosse; C Treboute; A Brelot; M Alizon
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

5.  Evolution of the human immunodeficiency virus type 1 envelope during infection reveals molecular corollaries of specificity for coreceptor utilization and AIDS pathogenesis.

Authors:  Q X Hu; A P Barry; Z X Wang; S M Connolly; S C Peiper; M L Greenberg
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

Review 6.  Early events of HIV-1 infection: can signaling be the next therapeutic target?

Authors:  Kate L Jones; Redmond P Smyth; Cândida F Pereira; Paul U Cameron; Sharon R Lewin; Anthony Jaworowski; Johnson Mak
Journal:  J Neuroimmune Pharmacol       Date:  2011-03-05       Impact factor: 4.147

7.  Variability in the human immunodeficiency virus type 1 gp120 Env protein linked to phenotype-associated changes in the V3 loop.

Authors:  Noah G Hoffman; Francoise Seillier-Moiseiwitsch; JaeHyung Ahn; Jason M Walker; Ronald Swanstrom
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

Review 8.  Genetic variation and HIV-associated neurologic disease.

Authors:  Satinder Dahiya; Bryan P Irish; Michael R Nonnemacher; Brian Wigdahl
Journal:  Adv Virus Res       Date:  2013       Impact factor: 9.937

9.  CD4-independent use of Rhesus CCR5 by human immunodeficiency virus Type 2 implicates an electrostatic interaction between the CCR5 N terminus and the gp120 C4 domain.

Authors:  G Lin; B Lee; B S Haggarty; R W Doms; J A Hoxie
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

10.  V3 recombinants indicate a central role for CCR5 as a coreceptor in tissue infection by human immunodeficiency virus type 1.

Authors:  S Y Chan; R F Speck; C Power; S L Gaffen; B Chesebro; M A Goldsmith
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.